SRPT missed EPS expectations by 376.24%
May 06, 2025, 10:33 PM
0.00%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
Sarepta Therapeutics (SRPT) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sarepta Therapeutics's actual EPS was -$4.60, missing the estimate of -$0.97 per share, resulting in a -376.24% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
